搜索结果

   CD1D

靶点ID:TCMBANKGE015117

靶点别名:CD1A; R3; R3G1

靶点描述:CD1d molecule

染色体:1

染色体位置:1q23.1

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:1637

OMIM_Link:188410

Ensembl_Link:ENSG00000158473

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN031363 dimethyl sulfoxide C2H6OS 78.14 g/mol CS(=O)C
TCMBANKIN033702 citric acid InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850 C6H8O7 192.12 C(C(=O)O)C(CC(=O)O)(C(=O)O)O
TCMBANKIN057142 Ruvoside UN2330; 1120-21-4; CAS-1120-21-4; LTBB002321; LS-158394; UN 2330; UNII-JV0QT00NUE; DSSTox_CID_1689; AI3-21126; U203; ACMC-209t6p; MolPort-001-783-218; Jsp000912; CCRIS 3796; Undecane [UN2330] [Flammable liquid]; EC 214-300-6; UND; undecyl group; 4-01-00-00487 (Beilstein Handbook Reference); KSC176C3J; Undecane; ANW-42095; 175476-97-8; DSSTox_RID_76285; AC1L23G2; n-Undecane, 99% 50g; Undekan; Undecane, 99%; QSPL 058; 17398EC4-D16F-42F6-8A27-60F8EC075469; BRN 1697099; Undecane, >=99%; TR-002350; InChI=1/C11H24/c1-3-5-7-9-11-10-8-6-4-2/h3-11H2,1-2H; UNDECAN-2-YL; MCULE-7319807036; NSC 66159; EINECS 214-300-6; J-002689; RSJKGSCJYJTIGS-UHFFFAOYSA-N; NCGC00254001-01; DTXSID9021689; n-C11H24; U0002; S0283; undecan; DSSTox_GSID_21689; SC-79237; CHEMBL132474; Undecane, analytical standard; JV0QT00NUE; MFCD00008959; Hendekan; HSDB 5791; CH3-[CH2]9-CH3; NCGC00247896-01; C-28174; CC-33184; N-UNDECANE; AKOS005145675; FT-0633353; AN-20593; 61193-21-3; 55101-35-4; KS-00000WJI; NSC66159; NSC-66159; I14-60624; ZINC1693211; Hendecane; Decane, methyl-; n-Hendecane; LMFA11000591; CHEBI:46342; TRA0090240; Undecane [UN2330] [Flammable liquid]; DB-041031; CTK0H6134; RTR-002350; Tox21_300076;LMFA11000001; Tridekan; InChI=1/C13H28/c1-3-5-7-9-11-13-12-10-8-6-4-2/h3-13H2,1-2H; CH3-[CH2]11-CH3; 629-50-5; 91490_FLUKA; 442713_SUPELCO; HSDB 5727; n-Tridecane; EINECS 211-093-4; NSC66205; T57401_ALDRICH; Tridecane; CHEBI:35998; NSC 66205; TRIDECANE, N-; C13834;Tridekan; UNII-114P5I43UJ component IIYFAKIEWZDVMP-UHFFFAOYSA-N; MCULE-7749861366; U393; DB-054344; Tridecane_GurudeebanSatyavani; ACMC-209t6w; C13H28; C13834; N-TRIDECANE; 757DB156-6441-49B0-A824-1532074AC0F6; NCGC00257175-01; IIYFAKIEWZDVMP-UHFFFAOYSA-N; Tridecane, >=99%; TL8004327; MolPort-003-933-018; LS-157141; AN-22061; STL301147; CAS-629-50-5; tridecan; LMFA11000001; SC-74775; AC1L1ZHL; LTBB002872; DSSTox_CID_7266; C-28190; InChI=1/C13H28/c1-3-5-7-9-11-13-12-10-8-6-4-2/h3-13H2,1-2H; Tridecane, 99.0%; TRA0008560; I14-59696; KSC353S8D; UNII-FW7807707B component IIYFAKIEWZDVMP-UHFFFAOYSA-N; S0285; Dodecane, methyl-; AKOS016011009; FT-0632663; Tridecane, analytical standard; Alkanes, C12-14; MFCD00008979; UNII-A3LZF0L939; DSSTox_GSID_27266; RT-000404; CHEMBL135694; tridecyl group; KS-00000XDT; ST24031950; HSDB 5727; EINECS 211-093-4; AC1Q28TY; DSSTox_RID_78377; FT-0082500; DTXSID6027266; CC-33178; A3LZF0L939; Tox21_303043; NSC-66205; Tridecane; CH3-[CH2]11-CH3; CTK2F3981; TRD; EC 211-093-4; NSC66205; AK115985; ANW-42102; 629-50-5; CHEBI:35998; NSC 66205; TRIDECANE, N-; ZINC1693738;n-tridecane;TRD C30H46O9 [C@]1([H])(OC([H])([H])[H])[C@@]([H])(O[H])[C@]([H])(C([H])([H])[H])O[C@@]([H])(O[C@@]2([H])C([H])([H])[C@]3([H])[C@@](C([H])([H])O[H])([C@@]([H])(C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@]([H])( C4=C([H])C(=O)OC4([H])[H])C([H])([H])C5([H])[H])[C@]56O[H])[C@@]6([H])C([H])([H])C3([H])[H])C([H])([H])C2([H])[H])[C@@]1([H])O[H]
TCMBANKIN057947 glucoside SCHEMBL25601; FT-0626726; 136760-05-9; .beta.-D-Glucose; UNII-J4R00M814D; beta-glucose; 207381-EP2280021A1; 133947-06-5; beta-delta-Glucopyranose; MCULE-4260589665; CHEBI:15903; beta-d-(+)-glucose; BDBM50240803; 28905-12-6; MolPort-006-111-449; KB-277820; DB02379; D07ONX; 6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrol; SC-25121; NSC759603; (1->6)-beta-D-glucopyranan; 1,2-beta-D-Glucan; EINECS 207-756-2; beta-D-Glc; (1,2-beta-D-glucosyl)n; (2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; .beta.-D-Glucopyranose; FT-0622903; NSC-759603; Beta-D-glucose anhydrous; b-D-Glucopyranose; CHEMBL1614854; beta-D-glucopyranose; W-202206; 1,5]; AC1L21QQ; C00221; Grape sugar; BG01505598; Galactitol,1,5-anhydro-1-C-phenyl-; G0047; 53991-51-8; 492-61-5; b-d-glucose; 9001-37-0; BGC; WQZGKKKJIJFFOK-VFUOTHLCSA-N; (1->3)-beta-D-glucan; CTK8F0914; AKOS016010209; DB-051616; AE-562/43459286; 207381-EP2280004A1; 50986-29-3; AK306225; (1->3)-beta-D-glucopyranan; TR-038298; beta-(1,3)-glucan; Curdlan; b-Glucose; .beta.-d-Glucose, anhydrous; ZINC3833800; CHEBI:27517; CHEBI:37671; FCH1120200; beta-Dextrose; (1->4)-beta-D-glucopyranan; (1->6)-beta-D-glucan; WURCS=1.0/1,0/[12122h; beta-D-glucose; (2R,3R,4S,5R,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; (1->2)-beta-D-glucopyranan; Pharmakon1600-01300015; ZYMOSAN; AJ-45802; (+)-Glucose; CHEBI:18246; 207381-EP2280020A1; (1->2)-beta-D-glucan; b-Dextrose; 108942-17-2; (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; MFCD00063989; 492-64-8; CHEBI:27380; (1->4)-beta-D-glucan; anhydrous glucose; Glucose, (beta-D)-Isomer; J4R00M814D; Callose; beta-D-Glucopyranose, anhydrous; Beta-d-glucose, anhydrous; 128009-02-9; AX8115243;BGC C6H12O6 180.16 g/mol C(C1C(C(C(C(O1)O)O)O)O)O
TCMBANKIN060996 UND C11H24 156.31 g/mol CCCCCCCCCCC
TCMBANKIN061003 Dodekan,dodecane,n-dodecane C12H26 170.33 g/mol CCCCCCCCCCCC
TCMBANKIN061016 tridecane C13H28 184.36 g/mol CCCCCCCCCCCCC
TCMBANKIN061058 n-hexadecane C16H34 226.44 g/mol CCCCCCCCCCCCCCCC
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000035 Digestive System Diseases; Infections - Disease or Syndrome disease
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI004674 - - Disease or Syndrome disease
TCMBANKDI007091 Neoplasms - Neoplastic Process phenotype
TCMBANKDI007782 Neoplasms - Neoplastic Process disease
TCMBANKDI009571 Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI010160 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI011174 Infections - Disease or Syndrome group
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI012074 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI014839 Nutritional and Metabolic Diseases; Immune System Diseases; Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI015452 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI015757 Infections - Disease or Syndrome disease
TCMBANKDI016252 Skin and Connective Tissue Diseases; Immune System Diseases - Disease or Syndrome disease
TCMBANKDI016946 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI023554 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI024402 Hemic and Lymphatic Diseases Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI025770 Infections - Disease or Syndrome disease
TCMBANKDI027040 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI031523 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome disease

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab